June 1, 2023
Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the...
Read More
June 1, 2023
SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th...
Read More
May 18, 2023
Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of...
Read More
April 20, 2023
Swiss Biotech Day 2023 April 24 & 25
Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development...
Read More
April 12, 2023
European Conference on Interventional Oncology (ECIO 2023) April 16 – 19
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European...
Read More
April 5, 2023
Indian Patent Office Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001
Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA). With this...
Read More
March 28, 2023
AngioDynamic International Life Symposium March 30 – April 1
Lu Alleruzzo, CEO & Co-Founder; and Tomas Hode, PhD, Co-Founder, CIO, & President were delighted to receive an invitation to...
Read More
February 1, 2023
Immunophotonics Presenting at BIO CEO & Investor Conference February 6 – 9, 2023
Immunophotonics, Inc. is grateful to NCI (the National Cancer Institute of NIH) and its SBIR Investor Initiatives Team for sponsoring...
Read More
January 26, 2023
Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications
Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety...
Read More
January 16, 2023
SIO Annual Scientific Meeting, January 19 – 23, 2023
Tomas Hode, PhD, Co-Founder, CIO, and President at @Immunophotonics, Inc. will be attending the Society of Interventional Oncology (SIO) 2023...
Read More